Direct-Abdominal chemo tested for tough stomach cancers
NCT ID NCT04220827
Summary
This early-stage study is testing whether delivering a chemotherapy drug called paclitaxel directly into the abdominal cavity is safe and tolerable for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find the highest dose that patients can handle without severe side effects. Researchers will also look for early signs that this treatment approach might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV GASTRIC CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.